|Bid||0.0000 x 3100|
|Ask||0.0000 x 2900|
|Day's range||3.7600 - 4.1000|
|52-week range||2.7700 - 5.7400|
|Beta (5Y monthly)||1.26|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Chiasma, Inc. (NasdaqGS: CHMA) to Amryt (NasdaqGS: AMYT). Under the terms of the proposed transaction, shareholders of Chiasma will receive 0.396 American Depositary Shares of Amryt for each share of Chiasma that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Chiasma, Inc. (NASDAQ: CHMA) to Amryt Pharma plc is fair to Chiasma shareholders. Under the terms of the agreement, each share of Chiasma common stock issued and outstanding prior to the consummation of the transaction will be exchanged for 0.396 Amryt American Depositary Shares, each representing five Amryt ordinary shares.